{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:29:28Z","timestamp":1785810568638,"version":"3.56.0"},"reference-count":32,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T00:00:00Z","timestamp":1714262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by the presence of the Philadelphia chromosome, a product of the reciprocal translocation t(9;22)(q34;q11), in the BCR and ABL genes. These rearrangements in both genes lead to the formation of various fusion mRNA products, with preferential expression of b2a2, b3a2, and other BCR::ABL1 mRNA variants, combined with additional chromosomal abnormalities. Notably, the distribution and frequency of different mRNA variants vary in different populations. However, studies concerning this in Mexico are limited, and the results have been inconclusive. This study therefore aimed to determine the distribution of BCR::ABL1 mRNA variants in different clinical phases of CML and their effect on hematological parameters and patient survival. This study included 33 patients, whose demographic, clinical, and molecular data on BCR::ABL1 mRNA variants and hematological parameters were collected to identify potential associations. A total of 84.8% (n = 28) of patients had BCR::ABL1 translocation and increased platelet and basophil counts. The most frequent mRNA variant was b3a2 (64.3%), followed by b2a2 (28.6%) and e1a2 (3.6%). Concerning the clinical phases of CML, 75.8% (n = 25), 21.2% (n = 7), and 3% (n = 1) of patients were in the chronic, blast, and accelerated phases, respectively. Moreover, the b3a2 mRNA variant was more commonly identified in patients in the chronic phase. No correlation was observed between mRNA variant expression and patient survival. However, b2a2 was indicative of patients with longer survival as well as those treated with imatinib or nilotinib. Additionally, platelet count could be a marker of BCR::ABL1 translocation.<\/jats:p>","DOI":"10.3390\/genes15050567","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T10:33:31Z","timestamp":1714559611000},"page":"567","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0722-1231","authenticated-orcid":false,"given":"Pablo","family":"Romero-Morelos","sequence":"first","affiliation":[{"name":"Departamento de Investigaci\u00f3n, Universidad Estatal del Valle de Ecatepec, Ecatepec 55210, Estado de M\u00e9xico, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0282-6354","authenticated-orcid":false,"given":"Ana","family":"Gonz\u00e1lez-Yebra","sequence":"additional","affiliation":[{"name":"Departamento de Ciencias Aplicadas al Trabajo, Divisi\u00f3n Ciencias de la Salud, Universidad de Guanajuato, Campus Le\u00f3n, Le\u00f3n 37670, Guanajuato, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anaid","family":"Herrer\u00edas-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Departamento de Medicina y Nutrici\u00f3n, Divisi\u00f3n Ciencias de la Salud, Universidad de Guanajuato, Campus Le\u00f3n, Le\u00f3n 37670, Guanajuato, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Ru\u00edz-Vel\u00e1zquez","sequence":"additional","affiliation":[{"name":"Departamento de Medicina y Nutrici\u00f3n, Divisi\u00f3n Ciencias de la Salud, Universidad de Guanajuato, Campus Le\u00f3n, Le\u00f3n 37670, Guanajuato, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Bueno-Rosario","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n, Hospital Regional de Alta Especialidad del Baj\u00edo, Servicios de Salud del Instituto Mexicano del Seguro Social para el Bienestar (IMSS-BIENESTAR), Le\u00f3n 37544, Guanajuato, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5639-5860","authenticated-orcid":false,"given":"Beatr\u00edz","family":"Gonz\u00e1lez-Yebra","sequence":"additional","affiliation":[{"name":"Departamento de Medicina y Nutrici\u00f3n, Divisi\u00f3n Ciencias de la Salud, Universidad de Guanajuato, Campus Le\u00f3n, Le\u00f3n 37670, Guanajuato, M\u00e9xico"},{"name":"Unidad de Investigaci\u00f3n, Hospital Regional de Alta Especialidad del Baj\u00edo, Servicios de Salud del Instituto Mexicano del Seguro Social para el Bienestar (IMSS-BIENESTAR), Le\u00f3n 37544, Guanajuato, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/sj.leu.2401565","article-title":"Chronic Myeloid Leukemia from Basics to Bedside","volume":"13","author":"Thijsen","year":"1999","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2019.04.011","article-title":"First-Line Imatinib in Elderly Patients with Chronic Myeloid Leukaemia from the CAMELIA Registry: Age and Dose Still Matter","volume":"81","author":"Belohlavkova","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1080\/13696998.2019.1618316","article-title":"Economic Modeling to Evaluate the Impact of Chronic Myeloid Leukemia Therapy Management on the Oncology Care Model in the US","volume":"22","author":"Jabbour","year":"2019","journal-title":"J. Med. Econ."},{"key":"ref_4","first-page":"105","article-title":"Response to Therapy, Treatment Intolerance and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real-World Cohort of Chronic Myeloid Leukaemia Patients","volume":"88","author":"McMullan","year":"2019","journal-title":"Ulster Med. J."},{"key":"ref_5","first-page":"686","article-title":"Treatment-Free Remission in Chronic Myeloid Leukemia","volume":"17","author":"Molica","year":"2019","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The Molecular Biology of Chronic Myeloid Leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1056\/NEJM198810133191506","article-title":"The Molecular Genetics of Philadelphia Chromosome\u2013Positive Leukemias","volume":"319","author":"Epstein","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_8","first-page":"e16914","article-title":"A Rare Case of P190 BCR-ABL Chronic Myeloid Leukemia with a Very Good Response to Tyrosine Kinase Inhibitors","volume":"13","author":"Gandhe","year":"2021","journal-title":"Cureus"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"The Proportion of Different BCR-ABL1 Transcript Types in Chronic Myeloid Leukemia. An International Overview","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"key":"ref_10","first-page":"338","article-title":"Prevalence of the BCR\/ABL1 Transcripts in Mexican Patients with Chronic Myelogenous Leukemia","volume":"59","year":"2007","journal-title":"Rev. Investig. Clin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ejh.12597","article-title":"Gender and BCR-ABL Transcript Type Are Correlated with Molecular Response to Imatinib Treatment in Patients with Chronic Myeloid Leukemia","volume":"96","author":"Lin","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e809","DOI":"10.1002\/mgg3.809","article-title":"Association of BCR\/ABL Transcript Variants with Different Blood Parameters and Demographic Features in Iraqi Chronic Myeloid Leukemia Patients","volume":"7","author":"Khazaal","year":"2019","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1196\/annals.1371.065","article-title":"Dangerous and Cancer-Causing Properties of Products and Chemicals in the Oil Refining and Petrochemical Industries. Part XXX","volume":"1076","author":"Mehlman","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/GO.21.00194","article-title":"Magnitude and Temporal Trend of the Chronic Myeloid Leukemia: On the Basis of the Global Burden of Disease Study 2019","volume":"7","author":"Hu","year":"2021","journal-title":"JCO Glob. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"107327482110384","DOI":"10.1177\/10732748211038429","article-title":"Clinicopathological Variables and Outcome in Chronic Myeloid Leukemia Associated With BCR-ABL1 Transcript Type and Body Weight: An Outcome of European LeukemiaNet Project","volume":"28","author":"Abdulla","year":"2021","journal-title":"Cancer Control"},{"key":"ref_16","first-page":"100172","article-title":"Atypical Chronic Myeloid Leukemia BCR-ABL 1 Negative: A Case Report and Literature Review","volume":"12","author":"Belkhair","year":"2019","journal-title":"Leuk. Res. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"gnw136","DOI":"10.1093\/geront\/gnw136","article-title":"Aging in Mexico: Population Trends and Emerging Issues","volume":"57","author":"Angel","year":"2016","journal-title":"Gerontologist"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.clml.2017.06.009","article-title":"Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated with Imatinib","volume":"17","author":"Pagnano","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.20452\/pamw.843","article-title":"Frequency of BCR-ABL Gene Mutations in Polish Patients with Chronic Myeloid Leukemia Treated with Imatinib: A Final Report of the MAPTEST Study","volume":"119","author":"Lewandowski","year":"2009","journal-title":"Pol. Arch. Med. Wewn."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1600-0609.2008.01170.x","article-title":"Correlation of BCR\/ABL Transcript Variants with Patients\u2019 Characteristics in Childhood Chronic Myeloid Leukaemia","volume":"82","author":"Adler","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.31557\/APJCP.2020.21.6.1545","article-title":"BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia","volume":"21","author":"Paramita","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_22","first-page":"65","article-title":"BCR-ABL Fusion Genes and Laboratory Findings in Patients with Chronic Myeloid Leukemia in Northeast Iran","volume":"9","author":"Ayatollahi","year":"2018","journal-title":"Casp. J. Intern. Med."},{"key":"ref_23","first-page":"13","article-title":"Frequency of P210 BCR-ABL Transcripts in 272 Bolivian Patients with Chronic Myeloid Leukemia (CML)","volume":"22","author":"Masias","year":"2016","journal-title":"Rev. M\u00e9dica La Paz"},{"key":"ref_24","first-page":"605","article-title":"Frequencies of the Breakpoint Cluster Region Types of the BCR\/ABL Fusion Gene in Mexican Mestizo Patients with Chronic Myelogenous Leukemia","volume":"56","year":"2004","journal-title":"Rev. Investig. Clin."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2257.2002.00413.x","article-title":"BCR\/ABL P210, P190 and P230 Fusion Genes in 250 Mexican Patients with Chronic Myeloid Leukaemia (CML)","volume":"24","author":"Garces","year":"2002","journal-title":"Clin. Lab. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.17533\/udea.iatreia.15539","article-title":"Frecuencia de Los Transcriptos P190BCR-ABL y P210BCR-ABL En Una Poblaci\u00f3n Colombiana Con Leucemia Mieloide Cr\u00f3nica (LMC) Usando RT-PCR Cualitativa","volume":"27","author":"Torres","year":"2014","journal-title":"Iatreia"},{"key":"ref_27","first-page":"247","article-title":"Frequency of BCR-ABL Fusion Transcripts in Iranian Patients with Chronic Myeloid Leukemia","volume":"11","author":"Yaghmaie","year":"2008","journal-title":"Arch. Iran. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/jcp.1041630321","article-title":"Differential Regulation of Integrin-Mediated Proplatelet Formation and Megakaryocyte Spreading","volume":"163","author":"Leven","year":"1995","journal-title":"J. Cell. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000065655","article-title":"Cytogenetic and Molecular Genetic Aspects of Chronic Myeloid Leukaemia","volume":"108","author":"Barnes","year":"2002","journal-title":"Acta. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0165-4608(95)00096-8","article-title":"Further Evidence for the Lack of Correlation between the Breakpoint Site within M-BCR and CML Prognosis and for the Occasional Involvement of P53 in Transformation","volume":"84","author":"Aguiar","year":"1995","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_31","first-page":"BR193-7","article-title":"Relationship of the BCR Gene Breakpoint and the Type of BCR\/ABL Transcript to Clinical Course, Prognostic Indexes and Survival in Patients with Chronic Myeloid Leukemia","volume":"8","author":"Prejzner","year":"2002","journal-title":"Med. Sci. Monit."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ajh.23238","article-title":"Early Landmark Analysis of Imatinib Treatment in CML Chronic Phase: Less than 10% BCR-ABL by FISH at 3 Months Associated with Improved Long-Term Clinical Outcome","volume":"87","author":"Ohm","year":"2012","journal-title":"Am. J. Hematol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/5\/567\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:34:58Z","timestamp":1760106898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/5\/567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,28]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["genes15050567"],"URL":"https:\/\/doi.org\/10.3390\/genes15050567","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,28]]}}}